BioParity.UFO / UAP research

2 sources for “Drug-combination research”

Results

PaperS7587

DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity

Benedict Anchang, Kara L. Davis, Harris G. Fienberg, Brian D. Williamson, Sean C. Bendall, Loukia G. Karacosta, Robert Tibshirani, Garry P. Nolan, Sylvia K. Plevritis. ebi.ac.uk. April 13, 2018.

DRUG-NEM ranks drug combinations using selected single-cell signaling responses. Its short-term surrogates and fixed-subpopulation assumptions limit interpretation. Repeated analyses are not new patients, and cell-line validation does not establish clinical benefit. The supplied main text is read; supporting information remains missing.

Supplied main text and mathematics read; apparatus partial
PaperS7603

Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line

Yapeng Su, Melissa E Ko, Hanjun Cheng, Ronghui Zhu, Min Xue, Jessica Wang, Jihoon W Lee, Luke Frankiw, Alexander Xu, Stephanie Wong, Lidia Robert, Kaitlyn Takata, Dan Yuan, Yue Lu, Sui Huang, Antoni Ribas, Raphael Levine, Garry P Nolan, Wei Wei, Sylvia K Plevritis, Guideng Li, David Baltimore, James R Heath. ebi.ac.uk. May 11, 2020.

The authors infer different routes to early drug tolerance within one cultured melanoma cell line and test selected drug combinations. The inferred barrier was not measured. Negative inhibitor assays, dependence among cell snapshots and possible normal-tissue toxicity qualify the results; clinical efficacy was not established.

Complete supplied main text; partial supplemental visuals

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach